GABAA receptor positive allosteric modulators

Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Ketones, Pregnanes, Sterols, Spacecraft, Ganaxolone, Spaceflight, Seizure, Maa, Orion, Ganaxolone, Marinus Pharmaceuticals, Orion Corporation, GANAXOLONE, MARINUS PHARMACEUTICALS, ORION CORPORATION

This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.

Key Points: 
  • This collaboration not only serves as an important step in our global development strategy for ganaxolone, it also represents the confidence Orion has in its potential.
  • Satu Ahomki, Senior Vice President, Commercial Operations of Orion Corporation said, We are pleased to be the partner of choice for Marinus in Europe.
  • What we have seen so far with ganaxolone is encouraging and signifies an ongoing commitment to the rare epilepsy communities.
  • Marinus expects to file a European marketing authorization application (MAA) for ganaxolone for the treatment of seizures associated with CDD by the end of Q3 2021.

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Orphan drugs, Ganaxolone, Pregnanes, Sedatives, Health care, Health, CDKL5 Deficiency Disorder, Ganaxolone, Marinus Pharmaceuticals, CDKL5 DEFICIENCY DISORDER, GANAXOLONE, MARINUS PHARMACEUTICALS

We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.

Key Points: 
  • We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.
  • Ganaxolone was generally well-tolerated with a safety profile consistent with previous clinical trials, with the most frequent adverse event being somnolence.
  • Marinus received Rare Pediatric Disease (RPD) Designation from the FDA for ganaxolone for the treatment of seizures associated with CDD in July 2020.
  • Further details are available in Marinus press release distributed August 3, 2021 (Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone).

Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, Mental health, Health, Pharmaceutical, Managed care, GABAA receptor positive allosteric modulators, Psychoactive drugs, Anticonvulsants, Chemical compounds, Health sciences, Ketones, Pregnanes, Sterols, CDKL5 deficiency disorder, Ganaxolone, CDKL5, Allosteric modulator

Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.

Key Points: 
  • Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
  • Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
  • Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.
  • Marinus completed the first ever Phase 3 pivotal trial in children with CDKL5 deficiency disorder last year and is conducting a Phase 2 trial in tuberous sclerosis complex and a Phase 3 trial in refractory status epilepticus.

Engrail Therapeutics Extends Series A Financing to $64 Million

Retrieved on: 
Tuesday, August 3, 2021
Pharmaceutical, Health, Clinical trials, GABAA receptor positive allosteric modulators, Branches of biology, Neurochemistry, Life sciences, gamma-Aminobutyric acid, Pharmacology, Engrail Therapeutics, Nan Fung Life Sciences, ENGRAIL THERAPEUTICS, NAN FUNG LIFE SCIENCES

Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.

Key Points: 
  • Engrail Therapeutics (Engrail) (the Company), a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies, today announced the close of a $32 million extension of its Series A financing round, which brings the total round to $64 million.
  • Nan Fung Life Sciences (NFLS), the global investment platform of the Nan Fung Group, led this round following their leadership of the original Series A raise.
  • Engrails lead compounds are subtype-selective GABA-A modulators with compelling pharmacological profiles that possess wide ranging therapeutic utility.
  • Founded in 2019, Engrail is forging a new direction to reduce the enormous burden of diseases that impact the nervous system.

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators - Indivior Commits $4 Million of New Funding

Retrieved on: 
Thursday, July 29, 2021
Branches of biology, Drugs, Neurochemistry, Indivior, GABAA receptor positive allosteric modulators, Allosteric regulation, gamma-Aminobutyric acid

As part of the extension, Indivior has committed $4 million of new funding to advance development of selected novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates discovered by Addex.

Key Points: 
  • As part of the extension, Indivior has committed $4 million of new funding to advance development of selected novel oral gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM) drug candidates discovered by Addex.
  • Excellent progress has been made in our research collaboration with Addex, said Christian Heidbreder, Chief Scientific Officer of Indivior.
  • With this new funding, Indivior has reiterated its commitment to advance this novel allosteric approach towards clinical evaluation.
  • Indivior PLC has licensed Addexs GABAB PAM program for the development of drug candidates with a focus in addiction.

freecoat nails Expands Clean Beauty Services with CBD Pedicures from Award-winning Brand Mazz Hanna

Retrieved on: 
Tuesday, July 27, 2021
Alkanes, Chemistry, Chemical substances, Physical sciences, Fuel gas, GABAA receptor positive allosteric modulators, Refrigerants, Pentane, Natural gas, Solvent, Butane, Pedicure

freecoat announced today that it has carefully selected the nationally acclaimed Mazz Hanna brand for its certified organic, cruelty-free products that will be offered as a CBD add-on with all pedicure services.

Key Points: 
  • freecoat announced today that it has carefully selected the nationally acclaimed Mazz Hanna brand for its certified organic, cruelty-free products that will be offered as a CBD add-on with all pedicure services.
  • "We're excited to offer our guests the ultimate 'feel good' pedicure with the CBD + Mazz Hanna add-on service," said freecoat nails co-founder Kat Eckles.
  • "We reviewed many CBD brands and chose Mazz Hanna because their commitment to health and wellness aligns with our mission as the nation's first clean, non-toxic beauty bar franchise.
  • Mazz Hanna CBD is certified organic with clean extraction methods that are free of toxic solvents such as propane, hexane, pentane, and butane.

Argus Launches LPG Freight Prices For Growing US And Middle East Exports

Retrieved on: 
Tuesday, July 27, 2021
Fuel gas, Industrial gases, Alkanes, GABAA receptor positive allosteric modulators, Refrigerants, Chemical substances, Chemistry, Propane, Argus Media, Butane, Ras Tanura

These prices are a response to market demand for greater transparency in the growing and increasingly complex global trade in LPG, which comprises butane and propane.

Key Points: 
  • These prices are a response to market demand for greater transparency in the growing and increasingly complex global trade in LPG, which comprises butane and propane.
  • Argus has worked with industry participants to develop prices that accurately reflect freight costs for LPG exports from the US to Brazil, Chile, Peru, Morocco and northwest Europe.
  • Argus has also launched VLGC and MGC freight rates on the Ras Tanura to New Mangalore route Saudi Arabia to India to support participants engaged in the swelling LPG trade between the Middle East and the sub-continent.
  • Argus Media chairman and chief executive Adrian Binks said: "The LPG industry seeks to better understand and manage its exposure to volatile freight costs.

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

Retrieved on: 
Tuesday, July 27, 2021
Food and Drug Administration, Drugs, Pharmaceutical industry, Health sciences, Health care, Drug Safety, GABAA receptor positive allosteric modulators, Lactams, PMDA, New Drug Application, Flunitrazepam

In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.

Key Points: 
  • In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.
  • Should approval be received, the company anticipates launch in the US in the second quarter of 2022, followed by other regions thereafter.
  • A New Drug Application (NDA) to the Japanese PMDA for clazosentan was submitted on March 1, 2021.
  • Based on initial clinical pharmacology investigation with ACT-541478, the company has decided not to pursue the development of this CNS compound further.

Claritas Cites Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe COVID-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107

Retrieved on: 
Monday, July 26, 2021
Chemistry, Physical sciences, Chemical elements, Gaseous signaling molecules, GABAA receptor positive allosteric modulators, Nitrogen cycle, Industrial gases, Oxides, Nitric oxide, Nitrogen, Nitrovasodilator, Oxide

In the cited study, inhaled nitric oxide was seen to significantly improve oxygen levels administered in patients with severe COVID-19 pneumonia.

Key Points: 
  • In the cited study, inhaled nitric oxide was seen to significantly improve oxygen levels administered in patients with severe COVID-19 pneumonia.
  • Following administration, R-107 enters the bloodstream, where it slowly releases nitric oxide systemically over 24 hours.
  • Nitric oxide is a natural molecule with antiviral properties that is produced by the body itself.
  • Professor Cuzzocrea has deep expertise regarding the medical use of nitric oxide and nitric oxide donors, and has published more than 600 papers on nitric oxide.

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, GABAA receptor positive allosteric modulators, Hypnotics, Muscle relaxants, Sedatives, Anxiolytic, Neurochemistry, Benzodiazepine

TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.

Key Points: 
  • TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.
  • We thank Mitacs for the funding and Carleton Universitys team, headed by Dr. Argel Aguilar-Valles at the Department of Neuroscience, for being an ideal partner to help us realize this vision."
  • The high rate of resistance to benzodiazepine and SSRIs for chronic anxiety disorder indicates an urgent unmet need for alternative anxiolytic treatments.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions.